Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects
Details
Publication Year 2021-09,Volume 13,Issue #17,Page 4479
Journal Title
Cancers
Publication Type
Research article
Abstract
Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.
Department(s)
Dental Oncology; Haematology
PubMed ID
34503289
Open Access at Publisher's Site
https://doi.org/10.3390/cancers13174479
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-05-30 08:01:47
Last Modified: 2025-05-30 08:02:20

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙